Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Project

Funding Information: The PSERENADE project is funded by the Bill and Melinda Gates Foundation as part of the World Health Organization Pneumococcal Vaccines Technical Coordination Project, grant number INV-010429/OPP1189065. Publisher Copyright: © 2021 by the authors.Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5-7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.publishersversionPeer reviewe

Changes in invasive pneumococcal disease caused by streptococcus pneumoniae serotype 1 following introduction of pcv10 and pcv13 : Findings from the pserenade project

Funding Information: Funding: The PSERENADE project is funded by the Bill and Melinda Gates Foundation as part of the World Health Organization Pneumococcal Vaccines Technical Coordination Project, grant num‐ ber INV‐010429/OPP1189065. Funding Information: Conflicts of Interest: KH conducted the study and analyses while working at the Johns Hopkins School of Public Health but is an employee at Pfizer, Inc. as of 26 October 2020. MDK reports grants from Merck, personal fees from Merck, and grants from Pfizer, outside the submitted work. JCB reports funding from Pfizer in the past year, unrelated to the submitted work. JAS reports grants from the Bill & Melinda Gates Foundation, the Wellcome Trust, the UK MRC, National Institute of Health Research, outside the submitted work. MCB reports lectures fee from MSD outside from submitted work. AS reports grants and personal fees from Pfizer and personal fees from MSD and Sanofi Pasteur, outside the submitted work. ML has been a member of advisory boards and has received speakers honoraria from Pfizer and Merck. German pneumococcal surveillance has been supported by Pfizer and Merck. SD reports grant from Pfizer, outside the submitted work. KA re‐ ports a grant from Merck, outside the submitted work. AvG as received researching funding from Pfizer (last year 2017, Pfizer Investigator‐Initiated Research [IIR] Program IIR WI 194379); attended advisory board meetings for Pfizer and Merck. CMA reports grants and personal fees from Pfizer, Qiagen and BioMerieux and grants from Genomica SAU, outside the submitted work. AM‐research support to my institution from Pfizer and Merck; honoraria for advisory board membership from GlaxoSmithKline, Merck and Pfizer. SNL performs contract research for GSK, Pfizer, Sanofi Pasteur on behalf of St. George’s University of London, but receives no personal remuneration. IY stated she was a member of mRNA‐1273 study group and has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi‐Pasteur, and Micron. RD has received grants/research support from Pfizer, Merck Sharp & Dohme and Medimmune; has been a scientific consultant for Pfizer, MeMed, Merck Sharp & Dohme, and Biondvax; had served on advisory boards of Pfizer, Merck Sharp & Dohme and Biondvax and has been a speaker for Pfizer. LLH reports research grants to her institution from GSK, Pfizer and Merck. JDK has received an unrestricted grant‐in‐aid from Pfizer Canada that sup‐ ports, in part, the CASPER invasive pneumococcal disease surveillance project. MH received an educational grant from Pfizer AG for partial support of this project. However, Pfizer AG had no role in the data analysis and content of the manuscript. MC has previously received a professional fee from Pfizer (Ireland), an unrestricted research grant from Pfizer Ireland (2007–2016) and an In‐ vestigator Initiated Reward from Pfizer Ireland in 2018 (W1243730). CLB, MD has intellectual prop‐ erty in BioFire Diagnostics and receives royalties through the University of Utah. CLB is an advisor to IDbyDNA. AK reports personal fees from Pfizer, outside the submitted work. MT reports grants from GlaxoSmithKline and grants from Pfizer Inc. to the Finnish Institute for Health and Welfare for research projects outside the submitted work, in which she has been a co‐investigator. JCS re‐ ports had received assistance from Pfizer for attending to scientific meetings outside the submitted work. SCGA received travel grant from Pfizer. BL had two research grants from Pfizer on Strepto‐ coccus pneumoniae. EV reports grants from French public health agency, during the conduct of the study; grants from Pfizer, grants from Merck, outside the submitted work. NBZ has received inves‐ tigator‐initiated research grants from GlaxoSmithKline, Takeda Pharmaceuticals, Merck and the Se‐ rum Institute of India, all unrelated to this research. CGS reports grant funding from Pfizer, Merck, and AstraZeneca in the past 3 years. NMvS reports grants and fee for service from Pfizer, fee for service from MSD and GSK, outside the submitted work; In addition, NMvS has a patent WO 2013/020090 A3 with royalties paid to University of California San Diego (inventors: Nina van Sorge/Victor Nizet). All other authors did not declare any conflicts of interest. The funders had no Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococ-cal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) con-taining ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERE‐ NADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) compar-ing the pre‐PCV10/13 period to each post‐PCV10/13 year by site using a Bayesian multi‐level, mixed-effects Poisson regression and all‐site IRRs using a linear mixed‐effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all‐site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.publishersversionPeer reviewe

Exploring the ring-closing metathesis for the construction of the solomonamide macrocyclic core: identification of bioactive precursors

New synthetic strategies directed toward the novel cyclopeptides solomonamides have been explored utilizing an olefin metathesis as the key reaction. In the various strategies investigated, we worked on minimally oxidized systems, and the olefin metathesis reaction demonstrated efficiency and validity for the construction of the macrocyclic core. The described synthetic strategies toward the solomonamides are well suited for the subsequent access to the natural products and represent flexible and diversityoriented routes that allow for the generation of a variety of analogues via oxidative transformations. In addition, preliminary biological evaluations of the generated solomonamide precursors revealed antitumor activity against various tumor cell lines.This work was financially supported by the Ministerio de Economía y Competitividad (MINECO) (ref BIO2014-56092-R, CTQ2014-60223-R and CTQ2016-76311-R) and Junta de Andalucía and “Fondo Europeo de Desarrollo Regional-FEDER” (P12 CTS-1507). I.C.-S. thanks Ministerio de Educación, Cultura y Deporte for a predoctoral fellowship (FPU programme)

Imported cases of malaria in Spain: observational study using nationally reported statistics and surveillance data, 2002-2015

BACKGROUND: Malaria was eliminated in Spain in 1964. Since then, more than 10,000 cases of malaria have been reported, mostly in travellers and migrants, making it the most frequently imported disease into this country. In order to improve knowledge on imported malaria cases characteristics, the two main malaria data sources were assessed: the national surveillance system and the hospital discharge database (CMBD). METHODS: Observational study using prospectively gathered surveillance data and CMBD records between 2002 and 2015. The average number of hospitalizations per year was calculated to assess temporal patterns. Socio-demographic, clinical and travel background information were analysed. Bivariate and multivariable statistical methods were employed to evaluate hospitalization risk, fatal outcome, continent of infection and chemoprophylaxis failure and their association with different factors. RESULTS: A total of 9513 malaria hospital discharges and 7421 reported malaria cases were identified. The number of reported cases was below the number of hospitalizations during the whole study period, with a steady increase trend in both databases since 2008. Males aged 25-44 were the most represented in both data sources. Most frequent related co-diagnoses were anaemia (20.2%) and thrombocytopaenia (15.4%). The risks of fatal outcome increased with age and were associated with the parasite species (Plasmodium falciparum). The main place of infection was Africa (88.9%), particularly Equatorial Guinea (33.2%). Most reported cases were visiting friends and relatives (VFRs) and immigrants (70.2%). A significant increased likelihood of hospitalization was observed for children under 10 years (aOR:2.7; 95% CI 1.9-3.9), those infected by Plasmodium vivax (4.3; 95% CI 2.1-8.7) and travellers VFRs (1.4; 95% CI 1.1-1.7). Only 4% of cases reported a correct regime of chemoprophylaxis. Being male, over 15 years, VFRs, migrant and born in an endemic country were associated to increased risk of failure in preventive chemotherapy. CONCLUSIONS: The joint analysis of two data sources allowed for better characterization of imported malaria profile in Spain. Despite the availability of highly effective preventive measures, the preventable burden from malaria is high in Spain. Pre-travel advice and appropriately delivered preventive messages needs to be improved, particularly in migrants and VFRs.This study has been funded by Instituto de Salud Carlos III through the project “PI15/01398” (Co-funded by European Regional Development Fund/European Social Fund “Investing in your future”).S

Nanographite: A highly active and durable metal-free ozonation catalyst with application in natural waters

[EN] The development of metal-free heterogeneous catalysts for advanced oxidation processes has emerged as a key focus for both academia and industry. We report on research that seeks to establish a correlation between the crystallographic, physicochemical, textural, and morphological properties of a series of graphite-based solids and their activities as metal-free ozonation catalysts in aqueous media. Our findings show that nanographite (NG) outperforms traditional graphite-based solids, activated carbon and Co3O4. The enhanced activity of NG is due to defective nanosized graphitic structures with high surface areas. NG exhibits an exceptional activity, durability, and recyclability that surpasses other known catalysts. Our study employs electron spin resonance and selective quenching experiments that reveal the generation of 1O2 during catalytic ozonation. Significantly, NG shows excellent catalytic efficiency even when using natural surface river water or seawater. This study illustrates the importance of the natural properties of graphite-based materials as active and durable ozonation catalysts in water.S.N. wishes to thank the Agencia Valenciana de la Innovacio for its financial support (AVI, INNEST/2020/111). S.N. also thanks the support received from Grant PID2021-123856OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by "ERDF A way of making Europe". S.N acknowledges the funding for open access charge from "CRUE-Universitat Politecnica de Valencia". A.D. is beneficiary of a grant Maria Zambrano in Universitat Politecnica de Valencia within the framework of the grants for the retraining in the Spanish university system (Spanish Ministry of Universities, financed by the European Union, NextGeneration EU).López-Francés, A.; Bernat-Quesada, F.; Cabrero-Antonino, M.; Ferrer Ribera, RB.; Amarajothi, DM.; Garcia-Baldovi, H.; Navalón Oltra, S. (2023). Nanographite: A highly active and durable metal-free ozonation catalyst with application in natural waters. Applied Catalysis B Environmental. 336. https://doi.org/10.1016/j.apcatb.2023.12292433

Iturri heated garments for extreme cold conditions

[EN] Biomechanics Institute of Valencia (IBV) participates in the project CENIT INFINITEX, coordinated by the company ITURRI, whose main objective is to develop a new generation of technical textiles, such as multifunctional textiles, which aims to integrate functionalities in a single textile; advanced textiles that offer high performance and specific technical characteristics; and intelligent textiles, capable to react under certain external stimuli. IBV has participated in the generation of specifications for the development of the different research lines; assessment for the development of the new technologies; and the evaluation of the demonstrators of the developed technologies during the Project. This paper presents the work carried out by IBV for ITURRI for the development of heated garments.[ES] El Instituto de Biomecánica (IBV) participa en el proyecto CENIT INFINITEX, coordinado por la empresa ITURRI, cuyo objetivo principal es desarrollar una nueva generación de textiles técnicos, entre ellos, textiles multifuncionales, que permiten integrar funcionalidades en un solo textil; textiles avanzados, que ofrecen unas altas prestaciones y tienen unas características técnicas muy específicas y textiles inteligentes, capaces de reaccionar en función de estímulos externos. El IBV ha participado en la generación de especificaciones para las distintas líneas de investigación, el asesoramiento para el desarrollo de las nuevas tecnologías y la evaluación de los demostradores de las tecnologías desarrolladas durante el proyecto. En este artículo se presenta el trabajo realizado por el IBV para ITURRI en el desarrollo de prendas calefactables.Agradecemos a la empresa ITURRI su liderazgo eficaz del consorcio, que ha hecho posible llevar este ambicioso proyecto a buen término. El proyecto INFINITEX se enmarca dentro de los proyectos CENIT (Consorcios Estratégicos Nacionales de Investigación Técnica) aprobados por el Ministerio de Ciencia e Innovación a través del Centro para el Desarrollo Tecnológico Industrial (CDTI).Gil Garcia, M.; Gonzalez Garcia, JC.; Priego Quesada, JI.; Pellicer Chenoll, MT.; Piqueras Fiszman, P.; Baydal Bertomeu, JM.; Dura Gil, J.... (2013). Prendas calefactables de ITURRI para combatir el frío extremo. Revista de biomecánica. 59:27-29. http://hdl.handle.net/10251/38694S27295